Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review
Sneller M, de Boer N, Everaars S, Schuurmans M, Guloksuz S, Cahn W, Luykx J. Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review. Frontiers In Psychiatry 2021, 12: 625935. PMID: 33868046, PMCID: PMC8044798, DOI: 10.3389/fpsyt.2021.625935.Peer-Reviewed Original ResearchSecond-generation antipsychoticsC-reactive proteinSchizophrenia spectrum disordersMetabolic syndromeCurrent BMIGenetic factorsHigher ageHigher white blood cell countSystematic reviewWhite blood cell countSevere mental illness experienceHigher baseline BMIRisk of MetS.Cardiovascular disease mortalityBlood cell countCross-sectional studyHigher current BMIMore studiesMental illness experienceSpectrum disorderSGA exposureBaseline BMICohort studyClinical factorsTobacco smokingStudy protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
de Boer N, Guloksuz S, van Baal C, Willebrands L, Deenik J, Vinkers C, Rossum I, Zinkstok J, Wilting I, Zantvoord J, Backx F, Swildens W, Schouw M, Bogers J, Hulshof F, de Knijff R, Duindam P, Veereschild M, Bak M, Frederix G, de Haan L, van Os J, Cahn W, Luykx J. Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. BMC Psychiatry 2021, 21: 4. PMID: 33402159, PMCID: PMC7783702, DOI: 10.1186/s12888-020-02992-4.Peer-Reviewed Original ResearchConceptsNetherlands Trial RegisterLifestyle interventionQuality of lifeTreatment inceptionOutcome measuresWeight gainAntipsychotic-induced weight gainSafety of metforminUse of metforminCommon adverse effectsSecondary outcome measuresPrimary outcome measureWeeks of treatmentBody weight lossMulti-center trialType 2 diabetesMajor health problemYears of ageSchizophrenia spectrum disordersTrials RegisterMetabolic syndromeOptimal management strategyExercise programMetformin treatmentDietary consultation